{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:10:17Z","timestamp":1763017817778,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.bbmt.2017.09.008","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T11:18:19Z","timestamp":1505906299000},"page":"1811-1812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Maintenance Rituximab after High-Dose Therapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Tobias","family":"Roider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.09.008_bib0010","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","article-title":"Patterns of survival in mantle cell lymphoma","volume":"6","author":"Zucca","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0015","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0020","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0030","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0035","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0040","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.bbmt.2017.07.006","article-title":"Long-term results of high-dose therapy and autologous stem cell transplantation for mantle cell lymphoma: effectiveness of maintenance rituximab","volume":"23","author":"Mei","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0045","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/cncr.25756","article-title":"Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma","volume":"117","author":"Dietrich","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0050","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","article-title":"Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"25","author":"Dietrich","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0055","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halld\u00f3rsd\u00f3ttir","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0060","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2013.332","article-title":"Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma","volume":"28","author":"Dietrich","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0065","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/annonc\/mdv364","article-title":"Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"26","author":"Graf","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0070","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.145.145","article-title":"Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 LyMa trial of the Lysa\/Goelams group","volume":"128","author":"Le Gouill","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0075","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0080","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","volume":"34","author":"Rummel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0085","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3109\/10428194.2011.580404","article-title":"Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network","volume":"52","author":"Kenkre","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0090","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.008_bib0095","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117307164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117307164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:59:00Z","timestamp":1761058740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117307164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1083879117307164"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.09.008","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance Rituximab after High-Dose Therapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}